Aim. To study the effectiveness and safety of pentahydroxyethylnaphtoquinone (Hystochrome) in patients with active and fibrous stages of retinopathy of prematurity. Methods. 281 prematurely born babies: first group - 63 patients with retinopathy of prematurity stages I-II and vast non-vascular area; second group - 201 baby with stage III retinopathy of prematurity and posterior aggressive form of retinopathy after the performed retinal laser photocoagulation; third group - 17 babies with subtotal intraocular hemorrhage - were followed up. In addition, 29 children with fibrous stage of retinopathy of prematurity were observed. Pentahydroxyethylnaphtoquinone (Hystochrome) was used as epibulbar instillations and peribulbar injections. To assess the treatment results, examination using the «RETCAM-120» system, B-scan ultrasonography using the «AVISO» scanner and visual evoked potentials examination with flash light stimulus using the «Neuro-MVP» device were performed. Results. In babies from the first group the improvement of electrophysiological parameters was observed in 20% of cases after treatment with pentahydroxyethylnaphtoquinone, compared to 4% in control group. In the second group pentahydroxyethylnaphtoquinone improved the electrophysiological parameters in 39% of cases. In the third group (17 babies with subtotal intraocular hemorrhage) the hemorrhage degradation was twice more rapid compared to controls. There was no effect from pentahydroxyethylnaphtoquinone treatment at the late stages of the disease. No adverse effects were registered. Conclusion. Pentahydroxyethylnaphtoquinone (Hystochrome) has shown good effectiveness and safety while treating patients with non-proliferative stages of retinopathy of prematurity and vitreous hemorrhage.
Objective: To assess the incidence of central serous chorioretinopathy (CSC) through the example of a large industrial Russian city.Methods: A retrospective analysis of CSC of Kazan population for 2009–2018 has been done.Results: From 2019 to 2018, 831 new cases of CSC were registered in Kazan. A statistically significant upward trend with growth rate 105.2% and accession rate 5.2% was typical for the annual track record. The mean age of patients was 50 years, the minimum age was 14 years, the maximum age was 87 years. A statistically significant upward trend was detected in track record of incidence in groups of 30–39-year-old and 40–49-year-old. Seasonal increase of the incidence was recorded in February, March, April, October, and November.Conclusions: The upward trend and seasonal prevalence are typical for longterm morbidity of CSC in Kazan. The highest morbidity rate of CSC and statistically significant upward trend of its incidence in track record were recorded in the age of 30–39.
Aim. To analyze the incidence of central serous chorioretinopathy among the Kazans population between 2009 and 2018.
Methods. A descriptive epidemiological study of the incidence of Central serous chorioretinopathy of the population of Kazan between 2009 and 2018 was conducted. It included an analysis of long-term changes in the incidence of male and female population and an assessment of the structure of morbidity by sex for the entire period and in dynamics. Testing for differences was performed using the nonparametric MannWhitney U test and Chi-square test with Yates correction.
Results. 831 new cases of central serous chorioretinopathy were registered in Kazan during 20092018, the ratio of men and women was approximately 1:1. In the dynamics of morbidity, the proportion of men increased from 24.2% in 2009 to 60.7% in 2018 (р=0.000002), while the proportion of women decreased from 75.8% in 2009 to 39.3% in 2018 (р=0.000002). The long-term dynamics for 20092018 is characterized by a statistically significant increase in the incidence rate of central serous chorioretinopathy in men (p=0.004) from 3.2 per 100 000 in 2009 to 14.8 per 100 000 in 2018. During the study period, the incidence rate in women remains at the same level, varying from 5.4 per 100 000 to 8 per 100 000 (p=0.663). Men are more likely to have central serous chorioretinopathy at a younger age (р=0.0001). The median age at the time of diagnosis in women was 55 years (Q25Q75 4565 years), in men 45 years (Q25Q75 3756 years).
Conclusion. From 2009 to 2018, the incidence rate of central serous chorioretinopathy among men in Kazan significantly increased in both intensive (p=0.004) and extensive indicators (p=0.000002); сentral serous chorioretinopathy in men develops at an earlier age compared with women (median age of women at the time of diagnosis was 55 years, median age of men 45 years, p=0.0001).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.